Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
05 sept. 2023 08h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
05 sept. 2023 07h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
14 août 2023 07h30 HE
|
Xilio Therapeutics, Inc.
Xilio entered into clinical trial collaboration with Roche to evaluate XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab (Tecentriq®), in patients with...
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
03 août 2023 16h05 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
25 mai 2023 17h01 HE
|
Xilio Therapeutics, Inc.
Encouraging preliminary anti-tumor activity observed in a patient with PD-L1 negative advanced non-small cell lung cancer Favorable preliminary safety profile for XTX101 observed at the recommended...
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
09 mai 2023 07h30 HE
|
Xilio Therapeutics, Inc.
Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK, PD, and anti-tumor activity data for XTX101, a tumor-activated, Fc-enhanced...
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 avr. 2023 16h05 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
02 mars 2023 16h05 HE
|
Xilio Therapeutics, Inc.
Initial clinical data from XTX101, XTX202 and XTX301 clinical trials anticipated in 2023 XTX202, a tumor-activated IL-2, demonstrated preliminary clinical pharmacodynamic evidence of tumor-selective...
Xilio Therapeutics to Present at Upcoming Investor Conferences
27 févr. 2023 07h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
16 févr. 2023 07h30 HE
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer,...